“Polygenic Adaptation”
Cancer Genetics, Inc. (NASDAQ:CGIX) stock enjoyed an overall uptrend of 11.94% from the beginning of 2019. The closing share price quoted for March 05, 2019 was $0.27. The 1.08% rally might have been tempting for an investor to buy at this point.
Illumina, the genome sequencing specialist, is a leader in a thriving market. Long-term investors should buy now, says Mike Tubbs.
The science of who we are and how we got here has advanced in leaps and bounds in recent years. Take genome sequencing, the process of identifying the order of genetic ‘letters’ in an organism’s DNA, or genetic code; ‘reading’ the genetic structure, essentially.
The whole human genome consists of three billion of these letters. It cost about $3bn and took 13 years for the very first decoding of a human genome to be completed in 2003. But today high-tech machines supplied by Illumina (Nasdaq: ILMN) do the same job for less than $1,000 in mere days.
Researchers have published what may be the validated largest family tree ever: a genealogy database stretching back 5 centuries that links 13 million people related by blood or marriage. The tree has already led to such insights as the link between genes and longevity and why our ancestors married whom they did. And researchers say that’s just a start.
“This study is an impressive and clever use of crowdsourcing data to address a number of interesting scientific questions,” says geneticist Peter Visscher of the University of Queensland in Brisbane, Australia, who was not involved with the work. The tree’s bigger promise, he and others say, could come if it were linked to health information to explore the role of genetics in diseases.
Arizona could soon be one of the first states to maintain a massive statewide DNA database.
And if the proposed legislation passes, many people — from parent school volunteers and teachers to real estate agents and foster parents — will have no choice but to give up their DNA.
Under Senate Bill 1475, which Sen. David Livingston, R-Peoria, introduced, DNA must be collected from anyone who has to be fingerprinted by the state for a job, to volunteer in certain positions or for a myriad of other reasons.
The bill would even authorize the medical examiner's office in each county to take DNA from any bodies that come into their possession.
The Department of Public Safety would maintain the collected DNA alongside the person's name, Social Security number, date of birth and last known address.
Any DNA in the database could be accessed and used by law enforcement in a criminal investigation. It could also be shared with other government agencies across the country for licensing, death registration, to identify a missing person or to determine someone's real name.
Report Scope:
This study is focused on the market side of genome editing and provides a comprehensive review of genome editing technologies, along with updates on the latest related progress in the field. Different market segments for this specific market are covered.
Download the full report: https://www.reportbuyer.com/product/3756560
Deep in the cells of the human immune system, DNA is constantly being replicated, transcribed and even mutated — but rarely does it change dramatically. Like every other living organism, humans and their genes developed from millions of years of evolutionary pruning.
But to Yale microbiologists, altering the entire genomes of T-cells — the body’s main offensive weapon against diseases such as cancer — is as simple as putting together a Lego set.
In a new study published in the journal Nature Methods on Feb. 25, researchers at the Sidi Chen Lab at Yale have come up with a new way to use the gene-editing technology CRISPR that significantly improves the technology’s efficiency. By allowing scientists to select multiple genes to include in the same CRISPR system, scientists will now be able to edit their samples’ genomes in one go, saving time and money in the process. These findings have considerable promise for engineering T-cells that can fight off cancers such as leukemia and lymphoma.
For just the second time, a patient with AIDS appears to have been cured of the disease after receiving a stem cell transplant from a donor with a genetic mutation that provides resistance to HIV, which causes AIDS. But the mutation is exceedingly rare, raising controversial questions of whether it may be replicated using nascent gene-editing tools like CRISPR/Cas9.
Scientists have revealed how certain wild plants with naturally doubled ‘supergenomes’ can stay ahead of the game when it comes to adapting to climate volatility and hostile environments.
This world-first study, published in Nature Ecology and Evolution,could have significant implications for plant and crop sustainability in the face of climate change.
NEW YORK (GenomeWeb) – Some large structural variants in the human genome exhibit population-specific patterns, according to a new analysis of more than 150 genome maps.
Large structural variants — those that are bigger than 2 kilobases — are difficult to detect, especially as short-read sequencing technologies are the most commonly used tools in genomic analysis.
For their study, Pui-Yan Kwok from the University of California, San Francisco and his colleagues analyzed optical genome maps generated for more than 150 individuals representing more than two dozen populations. A phylogenetic analysis of these maps indicated that some SVs and CNVs show variable population patterns. The researchers were also able to characterize SVs in typically intractable regions of the genome, including spots not covered by the human reference genome. Their results were published yesterday in Nature Communications.
Immunochemistry is a branch of science that deals with the study of the immune system. Immunochemical methods do not require extensive and destructive sample preparation and expensive instrumentation. Most immunochemical methods are based on simple photo, fluoro or luminometric detection. These methods have rapidly replaced chromatographic techniques in clinical diagnostics and offer fast detection of antibodies associated with specific diseases, hormones, disease biomarkers, and pharmaceuticals. Most commonly used assays in clinical immunochemistry involve either quantitative or qualitative formats using enzyme-linked immunosorbent assays (ELISAs), immunochromatography in the form of lateral-flow devices like dip-sticks and test strips, and Western Blot assays used to interpret data from protein analysis with gel electrophoresis. Moreover, it is also used in food safety assessment, environmental analysis, and the target chemical structures cover the widest range of molecular weight approximately hundreds of kilo Dalton (kD). Immunochemicals also develop antibody assays for cholera, anthrax, and diphtheria toxins.
Verastem Inc (NASDAQ:VSTM) institutional sentiment decreased to 1.12 in 2018 Q4. Its down -0.62, from 1.74 in 2018Q3. The ratio has dropped, as 48 hedge funds started new and increased equity positions, while 43 sold and trimmed holdings in Verastem Inc. The hedge funds in our partner’s database now have: 41.14 million shares, up from 34.34 million shares in 2018Q3. Also, the number of hedge funds holding Verastem Inc in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 20 Reduced: 23 Increased: 28 New Position: 20.
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $225.80 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.
Both Verastem Inc. (NASDAQ:VSTM) and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.
What makes a pathogen successful? What determines a plant’s ability to defend itself against an invader? The outcome of a myriad of encounters between plants and their pathogens have preoccupied humans since the dawn of agriculture. Crop diseases have a devastating economic impact that reaches billions of dollars annually and are a recurring global threat to food production (Horvath 2018). Discovering the key that unlocks the code of plant-pathogen interactions has motivated extensive research on the molecular determinants of pathogen virulence and plant resistance, and on devising strategies to apply this knowledge in modern agricultural practices.
The connection between an influenza virus surface protein and a host cell lipid has been discovered by researchers at the University of Maine and the National Institutes of Health. Confirmation of direct interaction between the protein and lipid could lead to new antiviral therapies.
Report Titled “Epigenetics Market Exploration Report Forecast 2019-2025” includes a comprehensive study of the important sections to provide insights on the Epigenetics Market dynamics till 2025, which would enable the stakeholders to capitalize on prevailing market opportunities, newest industry data and Epigenetics Industry future trends, allowing you to identify the products and end users driving Revenue growth and effectiveness.
Despite being globally infrequent, testicular germ cell tumors (TGCTs) represent the most common neoplasms in young adult Caucasian men. They are challenging tumors, hallmarked by striking heterogeneity; however, they show very few mutations and share the same (almost) unifying cytogenetic abnormality, in the form of isochromosome 12p. This leaves room for Epigenetic phenomena to explain such diversity. Epigenetic mechanisms frequently deregulated in various cancer types include DNA methylation, non-coding RNAs, but also the effect on chromatin accessibility subsequent to histone post-translational modifications (PTMs) and to the action of chromatin remodeling complexes (ChRCs). These modifications are introduced by complex families of enzymes (DNA and histone modifying enzymes) which show, naturally, deregulated expression in cancer. However, and despite epigenetic (de)regulation being especially relevant in TGCTs, few studies have addressed the role of these enzymes in this tumor model.
The genome editor CRISPR has transformed many areas of biology, but using this tool to enhance certain varieties of crops such as wheat and corn remains difficult because of the plants’ tough cell walls. Now, a major agricultural company has creatively solved that problem by using pollen from one genetically modified plant to carry CRISPR’s components into another plant’s cells. The solution promises to speed the creation of better and more versatile crops, scientists say.
CRISPR-Cas9 genome editing therapy has been shown by the Salk Institute team to suppress the accelerated aging observed in mice with Hutchinson-Gilford Progeria syndrome; and provided insight into the molecular pathways involved in accelerated aging, and how to reduce toxic proteins via gene therapy.
NEW YORK (GenomeWeb) – In a study published in Science late last week, researchers from the US, China, and Germany reported a new method they've developed to detect off-target mutations created from editing one blastomere of two-cell mouse embryos using either CRISPR-Cas9 or one of two base editing technologies.
This method — named GOTI (Genome-wide Off-target analysis by Two-cell embryo Injection) — found that off-target single nucleotide variants (SNVs) were rare in embryos edited by CRISPR-Cas9 or the adenine base editor 7.10 (ABE7.10), which both caused off-target effects with a frequency close to the spontaneous mutation rate. However, the researchers also found that the cytosine base editor 3 (BE3) induced SNVs with frequencies more than 20-fold higher than the spontaneous mutation rate.
Dante Labs takes the first step of its ambitious project to integrate high coverage genome sequencing in clinical care in clinics and hospitals.
Dante Labs has announced the first of hundreds of European clinics which will integrate whole genome and whole exome sequencing in standard clinical care, further making personalized medicine a standard within the European health care system.
The clinic, "Villa Letizia," is located in L’Aquila, Italy, and is the selected destination for patients across the entire Mediterranean region. Patients will receive 100X whole exome or 30X whole genome sequencing with premium turnaround time and personalized reports as part of their standard clinical care.
